Pharmaceutical Targeting the Envelope Protein of SARS-CoV-2: the Screening for Inhibitors in Approved Drugs

About this item

Title

Pharmaceutical Targeting the Envelope Protein of SARS-CoV-2: the Screening for Inhibitors in Approved Drugs

Content partner

FigShare

Collection

FigShare

Description

An essential overview of the biological role of coronavirus viroporin (envelope protein) is given, together with the effect of its known inhibitors on the life cycle of coronavirus. A docking study is conducted using a set of known drugs approved worldwide (ca. 6000 compounds) on a structure of the SARS-CoV-2 viroporin modelled from the published NMR-resolved structures. The screening has identified 36 promising drugs currently on the market, which could be proposed for pre-clinical tr...

Read more

Format

Other

Date created

14 May, 2020

Creator

Anatoly Chernyshev

URL

https://figshare.com/articles/preprint/Pharmaceutical_Targeting_the_Envelope_Protein_of_SARS-CoV-...

Related subjects

SARS-CoV-2 / E protein / viroporin / repurposing / docking / Drug Discovery and Drug Delivery Systems

What is the copyright status of this item?

Creative Commons

This item appears to be licensed under a Creative Commons Attribution (BY) CC International license.

More Information

FigShare has this to say about the rights status of this item:

http://figshare.com/licensing

You can learn more about the rights status of this item at: http://creativecommons.org/licenses/by/4.0

What can I do with this item?

You must always check with FigShare to confirm the specific terms of use, but this is our understanding:

Non-infringing use

NZ Copyright law does not prevent every use of a copyright work. You should consider what you can and cannot do with a copyright work.

Share it

This item is suitable for copying and sharing with others, without further permission.

Modify it

This item is suitable for modifying, remixing and building upon, without further permission.

Use it commercially

This item is suitable for commercial use, without further permission.